Diltiazem Treatment for Pre-Clinical Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers
Carolyn Y. Ho(Brigham and Women's Hospital), Christine E. Seidman(Harvard University), Christopher Semsarian(The University of Sydney), Elliott M. Antman(Brigham and Women's Hospital), E. John Orav(Harvard University), Begoña López(Universidad de Navarra), Neal K. Lakdawala(Brigham and Women's Hospital), Javier Dı́ez(Instituto de Salud Carlos III), Allison L. Cirino(University of Campania "Luigi Vanvitelli"), Steven E. Lipshultz(Jacobs Institute), Siddique Abbasi(Brigham and Women's Hospital), Raymond Y. Kwong(Broad Institute), Steven D. Colan(Boston Children's Hospital), Elizabeth Sparks(The Ohio State University), Arantxa González(Instituto de Salud Carlos III)
Cited by 158
Related Papers
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2013|5.1k
Contemporary Definitions and Classification of the Cardiomyopathies
|Circulation|2006|3.4k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
|Circulation|2011|2.1k